The Cambridge Nutraceuticals Team

Tim DyeTim Dye – Executive Chairman

Tim is a serial entrepreneur who has successfully built and sold businesses in several different sectors.

He was previously a non-executive director at Abcam plc, and prior to Abcam plc, he was Chief Executive and then Chairman of Ransom plc, which he built into one of the UK’s largest natural healthcare groups. He is an active angel investor and is a member of the Cambridge Angels investor group. Appointed as Cambridge Nutraceuticals’s CEO as part of the December 2012 financing round, in April 2015, on the appointment of Adam Cleevely as CEO, he took the role of Executive Chairman. He is also a trustee of the Whitley Fund for Nature. Tim is an Economics Exhibitioner and graduate of Cambridge University.

Adam CleeveyAdam Cleevely – CEO

Adam has extensive experience in small and medium companies and particularly ecommerce.

He has worked at Abcam, running the Business Intelligence and Opportunities department, managing teams of analysts and project managers. He also was Operations Director of Hubbub, an online food delivery business in London and worked as a management consultant for Newton Europe. He has held a non executive directorship at Bocca di Lupo, London’s acclaimed Italian restaurant, since it was founded. He holds an MEng in Engineering, Economics and Management from Oxford University

Eddie pic
Eddie Powell – CFO

Eddie was CFO of Abcam plc from 2000 to 2007, during which time the business expanded from sales of £275k to £25m.

Among other things, Eddie managed the IPO of the business in 2005. He and his family lead-financed, and he personally managed, the acquisition from the administrators of the assets of Cambridge Theranostics Ltd (‘CTL’) in 2012. Eddie is a Chartered Accountant and has a PhD in Chemistry from Cambridge University.

Chris MeaneyChris Meaney – Business Development Manager

Chris has been involved with Ateronon from the start.

Chris has extensive experience in over the counter and generic pharmaceutical product management, as well as 3 years’ product marketing management with Lloyds Pharmacy.

Oliver ElliotOliver Elliot – Data Scientist

Until joining Cambridge Nutraceuticals in April 2015, Oli worked at Abcam plc as Statistical Analyst, leading a team of analysts developing innovative improvements to the company’s operational systems.

He holds an MSci in Mathematics from the University of Bristol.

Nadia Saif – Marketing and Customer Service ExecutiveNadia Saif – Marketing and Customer Service Executive

Nadia holds a first class degree in Medical Microbiology from the University of Surrey.

Since graduating from university, Nadia has explored her love of science in a variety of companies including, a CRO, a biotechnology company and a medical communications agency. In her spare time Nadia participates in local musicals in and around Cambridge.


Professor-Alf-LindbergProfessor Alf Lindberg MD, PhD

A veteran scientist who was a former secretary of the Nobel Prize Committee for Physiology and Medicine, Dr Lindberg has also spent much of his career as a professor at Sweden’s prestigious Karolinska Institute in Stockholm.

Alf was also previously head of research at Wyeth and at Aventis. He now uses a lifetime of his own expertise and knowledge collected from years of contact with some of the world’s most respected minds, and travels the world as an advisor and consultant to a variety of big pharmaceutical and biotechnology companies.


Peter-KirkpatrickPeter Kirkpatrick – FRCS (SN) FMedSci

Peter Kirkpatrick is Ateronon’s key medical advisor. He is a senior specialist neurosurgeon at Addenbrooke’s Hospital, a world-class centre of medical expertise.

The hospital is affiliated to the University of Cambridge and makes up a part of the research-based Cambridge Bio-Medical Campus.

Mr Kirkpatrick is a leading expert on strokes and arterial and vascular disease affecting the brain, and has published more than 200 studies. He is also president of the Cambridgeshire branch of Headway, the brain injury charity, and has been a major fund-raiser for their work. His input into the analysis of research on Ateronon, and advice on future research priorities, is invaluable to the development of the business